Pharmacological treatment of portal hypertension: Present and future

Journal of Hepatology

Volumn 28, Issue 5, 1998, Pages 896-907

  Lebrec, Didier ^a  

^a BEAUJON HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLONIDINE; GLYCERYL TRINITRATE; ISOSORBIDE 5 NITRATE; KETANSERIN; MOLSIDOMINE; OCTREOTIDE; PRAZOSIN; PROPRANOLOL; RITANSERIN; SPIRONOLACTONE; TERLIPRESSIN; VASOPRESSIN;

COLLATERAL CIRCULATION; ENDOSCOPIC SCLEROTHERAPY; GASTROINTESTINAL HEMORRHAGE; META ANALYSIS; PORTAL HYPERTENSION; PORTAL VEIN BLOOD PRESSURE; PRIORITY JOURNAL; REVIEW;

EID: 0032079773     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(98)80241-9     Document Type: Review

References (106)

1. Lebrec D, de Fleury P, Rueff B, Nahum H, Benhamou JP. Portal hypertension, size of esophageal varices, and risk of gastrointestinal bleeding in alcoholic cirrhosis. Gastroenterology. 79:1980;1139-1144.
2. Garcia-Tsao G, Groszmann RJ, Fisher RL, Conn HO, Atterbury CE, Glickman M. Portal pressure, presence of gastroesophageal varices and variceal bleeding. Hepatology. 5:1985;419-424.
3. Lebrec D. Pharmacological treatment of portal hypertension: hemodynamic effects and prevention of bleeding. Pharmacol Ther. 64:1994;65-107.
4. Lebrec D, Nouel O, Corbic M, Benhamou JP. Propranolol: a medical treatment for portal hypertension. Lancet. i:1980;121-124.
5. Lebrec D, Poynard T, Hillon P, Benhamou JP. Propranolol for prevention of gastrointestinal bleeding in patients with cirrhosis. A controlled study. N Engl J Med. 305:1981;1371-1374.
6. Hillon P, Lebrec D, Munoz C, Jungers M, Goldfarb G, Benhamou J.P. Comparison of the effects of a cardioselective and a nonselective β-blocker on portal hypertension in patients with cirrhosis. Hepatology. 2:1982;528-531.
7. Hayes PC, Davis JM, Lewis JA, Bouchier IA. Meta-analysis of value of propranolol in prevention of variceal haemorrhage. Lancet. 336:1990;153-156.
8. Pagliaro L, Burroughs AK, Sorensen Tl, Lebrec D, Morabito A, D'Amico G. Therapeutic controversies and randomised controlled trials (RCTs): prevention of bleeding and rebleeding in cirrhosis. Gastroenterol Int. 2:1989;71-84.
9. Bernard B, Lebrec D, Mathurin P, Opolon P, Poynard T. Beta-adrenergic antagonists in the prevention of gastrointestinal rebleeding in patients with cirrhosis: a meta-analysis. Hepatology. 25:1997;64-70.
10. Marbet UA, Straumann A, Gyr KE, Beglinger C, Schaub N, Vögtlin J, et al. Reduction in early recurrence of variceal bleeding by propranolol. Scand J Gastroenterol. 23:1988;369-374.
11. Perez-Ayuse RM, Pique JM, Bosch J, Panes J, Gonzales A, Perez R, et al. Propranolol in prevention of recurrent bleeding from severe portal hypertensive gastropathy in cirrhosis. Lancet. 337:1991;1431-1434.
12. Poynard T, Lebrec D, Hillon P, Sayegh R, Bernuau J, Naveau S, et al. Propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a prospective study of factors associated with rebleeding. Hepatology. 7:1987;447-451.
13. Lebrec D, Bernuau J, Rueff B, Benhamou JP. Gastrointestinal bleeding after abrupt cessation of propranolol administration in cirrhosis. N Engl J Med. 307:1982;560.
14. Bernard B, Lebrec D, Mathurin P, Opolon P, Poynard T. Propranolol and sclerotherapy in the prevention of gastrointestinal rebleeding in patients with cirrhosis: a meta-analysis. J Hepatol. 26:1997;312-324.
15. D'Amico G, Pagliaro L, Bosch J. The treatment of portal hypertension. A meta-analytic review. Hepatology. 22:1995;332-354.
16. Gregory PB. Sclerotherapy for actively bleeding esophageal varices in male alcoholics with cirrhosis: results of a randomized, multicenter clinical trial. Gastroenterology. 98:1990;A53.
17. Groszmann RJ, Bendtsen F, Bosch J, Fleig W, Grace N, Lebrec D, et al. Baveno II Consensus Statements: Drug Therapy for Portal Hypertension. De Franchis R. Portal Hypertension II. 1996;98-99 Blackwell Science.
18. Groszmann RJ, Kravetz D, Bosch J, Glickman M, Bruix J, Bredfeldt J, et al. Nitroglycerin improves the hemodynamic response to vasopressin in portal hypertension. Hepatology. 2:1982;757-762.
19. Walker S, Stiehl A, Raedsch R, Kommerell B. Terlipressin in bleeding oesophageal varices. A placebo controlled double-blind study. Hepatology. 6:1986;112-115.
20. Freeman JG, Cobden I, Record CO. Placebo-controlled trial of terlipressin (Glypressin) in the management of acute variceal bleeding. J Clin Gastroenterol. 11:1989;58-60.
21. Söderlund C, Magnusson I, Torngren S, Lundell L. Terlipressin (triglycyl-lysine vasopressin) controls acute bleeding oesophageal varices. A double-blind, randomized, placebo-controlled trial. Scand J Gastroenterol. 25:1990;622-630.
22. Colin R, Giuili N, Czernichow P, Ducrotte P, Lerebours E. Prospective comparison of glypressin, tamponade and their association in the treatment of bleeding esophageal varices. Lebrec D, Blei AT. Vasopressin Analogs and Portal Hypertension. 1987;149-153 John Libbey Eurotext, Paris.
23. Fort E, Sautereau D, Silvain C, Ingrand P, Pillegand B, Beauchant M. A randomized trial of terlipressin plus nitroglycerin vs balloon tamponade in the control of acute variceal hemorrhage. Hepatology. 11:1990;678-681.
24. Feu F, D'Amico G, Bosch J. The acute bleeding episode: advances in drug therapy. Aroyo V, Bosch J, Rodés J. Treatments in Hepatology. 1995;9-22 Masson, Paris.
25. Cerini R, Lee SS, Hadengue A, Koshy A, Girod C, Lebrec D. Circulatory effects of somatostatin analogue in two conscious rat models of portal hypertension. Gastroenterology. 94:1988;703-708.
26. Hanisch E, Doertenbach J, Usadel KH. Somatostatin in acute bleeding oesophageal varices. Pharmacology and rationale for use. Drug. 44:1992;24-35. (Suppl. 2).
27. Valenzuela JE, Schubert T, Fogel MR, Strong RM, Levine J, Mills PR, et al. A multicenter, randomized, double-blind trial of somatostatin in the management of acute hemorrhage from esophageal varices. Hepatology. 10:1989;958-961.
28. Gotzsche PC, Gjorup I, Bonnen H, Brahe NEB, Becker U, Burcharth F. Somatostatin ν placebo in bleeding oesophageal varices: randomised trial and meta-analysis. Br Med J. 310:1995;1495-1498.
29. Burroughs AK, McCormick PA, Hughes MD, Sprengers D, D'Heygere F, McIntyre N. Randomized, double-blind trial, placebo-controlled trial of somatostatin for variceal bleeding. Emergency control and prevention of early variceal rebleeding. Gastroenterology. 99:1990;1388-1395.
30. The North Italian Endoscopic Club for the Study and Treatment of Esophageal Varices. Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices. A prospective multicenter study N Engl J Med. 319:1988;983-989.
31. Poynard T, Calès P, Pasta L, Idéo G, Pascal JP, Pagliaro L, et al. Beta-adrenergic-antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices: an analysis of data and prognostic factors in 589 patients from four randomized clinical trials. N Engl J Med. 324:1991;1532-1538.
32. Pagliaro L, D'Amico G, Sorensen TIA, Lebrec D, Burroughs AK, Morabito A, et al. Prevention of first bleeding in cirrhosis. A metaanalysis of randomized trials of non-surgical treatment. Ann Intern Med. 77:1992;59-70.
33. Bahathal PS, Grossman HJ. Reduction of the increased portal vascular resistance of the isolated perfused cirrhotic rat liver by vasodilators. J Hepatol. 1:1985;325-327.
34. Garcia-Pagan JC, Navasa M, Bosch J, Bru C, Pizcueta P, Rodés J. Enhancement of portal pressure reduction by the association of isosorbide-5-mononitrate to propranolol administration in patients with cirrhosis. Hepatology. 11:1990;230-238.
35. Villanueva C, Balanzo J, Novella MT, Soriano G, Sainz S, Torras X, et al. Nadolol plus isosorbide mononitrate compared with sclerotherapy for the prevention of variceal rebleeding. N Engl J Med. 334:1996;1624-1629.
36. Feu F, McCormick PAA, Planas R, Burroughs AK, Bosch J. Randomized controlled trial comparing propranolol+isosorbide-5-mononitrate vs shunt surgery/sclerotherapy in the prevention of variceal bleeding. J Hepatol. 23:1995;69. (suppl. 1).
37. Merkel C, Marin R, Enzo E, Donada C, Cavallarin G, Torboli P, et al. Randomised trial of nadolol alone or with isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis. Lancet. 348:1996;1677-1681.
38. Masilah C, Gournay J, Martin T, Schnee M, Graf E, Perin D. 5-mononitrate d'isosorbide associé au propranolol contre propranolol seul après hémorragie par rupture de varices oesophagiennes: une étude randomisée. Gastroenterol Biol Clin. 21:1997;A87.
39. Angelico M, Carli L, Piat C, Gentile S, Rinald V, Bologna E, et al. Isosorbide-5-mononitrate versus propranolol in the prevention of first bleeding in cirrhosis. Gastroenterology. 104:1993;1460-1465.
40. Salerno F, Borroni G, Cazzaniga M, Bissoli F, Lorenzano E, Maggi A, et al. Nadolol and isosorbide-5-mononitrate for preventing bleeding in cirrhotics with ascites. J Hepatol. 25:1996;92. (suppl. 1).
41. Angelico M, Carli L, Piat C, Gentile S, Capocaccia L. Effects of isosorbide-5-mononitrate compared with propranolol on first bleeding and long-term survival in cirrhosis. Gastroenterology. 113:1997;1632-1639.
42. Fiaccadori F, Pedretti G, Biraghi M, Arcidiacono R. Terlipressin and endoscopic sclerotherapy control variceal bleeding and prevent early rebleeding in cirrhotic patients. Curr Ther Res. 54:1993;1-10.
43. Sung JJY, Chung SCS, Yung MY, Lai CW, Lau YW, Lee YT, et al. Prospective randomised study of effect of octreotide on rebleeding from oesophageal varices after endoscopic ligation. Lancet. 346:1995;1666-1669.
44. Primignani M, Andreoni B, Carpinelli L, Capria A, Rocchi G, Lorenzini I, et al. Sclerotherapy plus octreotide versus sclerotherapy alone in the prevention of early rebleeding from esophageal varices: a randomized, double-blind, placebo-controlled, multicenter trial. Hepatology. 21:1995;1322-1327.
45. Besson I, Ingrand P, Person B, Boutroux D, Heresbach D, Bernard P, et al. Sclerotherapy with or without octreotide for acute variceal bleeding. N Engl J Med. 333:1995;555-560.
46. Avgerinos A, Nevens F, Raptis S, Fevery J. Early administration of somatostatin and effficacy of sclerotherapy in acute oesophageal variceal bleeds: the European acute bleeding oesophageal variceal episodes (ABOVE) randomised trial. Lancet. 350:1997;1495-1499.
47. Double blind act of 5 day octreotide versus placebo, associated with sclerotherapy for trial/failures. Hepatology. 24:1996;352A.
48. Randomized controlled trial of sclerotherapy vs somatostatin infusion in the prevention of early rebleeding following variceal hemorrhage in patients with cirrhosis. J Hepatol. 21:1994;7. (suppl. 1).
49. for the treatment of bleeding esophageal varices. Randomized controlled trial comparing terlipressin vs endoscopic injection sclerotherapy in the treatment of acute variceal bleeding and prevention of early rebleeding Hepatology. 26:1997;249A.
50. Levacher S, Letoumelin P, Pateron D, Blaise M, Lapandry C, Pourriat JL. Early administration of terlipressin plus glyceryl trinitrate to control active upper gastrointestinal bleeding in cirrhotic patients. Lancet. 346:1995;865-868.
51. Lin HC, Soubrane O, Cailmail S, Lebrec D. Early chronic administration of propranolol reduces the severity of portal hypertension and portal-systemic shunts in conscious portal vein stenosed rats. J Hepatol. 13:1991;213-219.
52. Sarin SK, Groszmann RJ, Mosca PG, Rojkind M, Stadecker MJ, Bhatnagar R, et al. Propranolol ameliorates the development of portal-systemic shunting in a chronic murine schistosomiasis model of portal hypertension. J Clin Invest. 87:1991;1032-1036.
53. Lin HC, Soubrane O, Lebrec D. Prevention of portal hypertension and portosystemic shunts by early chronic administration of clonidine in conscious portal vein-stenosed rats. Hepatology. 14:1991;325-330.
54. Plevris JN, Elliot R, Mills PR, Hislop WS, Davies JM, Bouchier IAD, et al. Effect of propranolol on prevention of first variceal bleed and survival in patients with chronic liver disease. Aliment Pharmacol Ther. 8:1994;63-70.
55. Propranolol does not decrease the development of large esophageal varices in patients with cirrhosis. A controlled study. Hepatology. 22:1995;155A.
56. Brenner DA, Alcorn JM. Therapy for hepatic fibrosis. Semin Liver Dis. 10:1990;75-83.
57. Moreau R, Lebrec D. Endogenous factors involved in the control of arterial tone in cirrhosis. J Hepatol. 22:1995;370-376.
58. B receptors. J Hepatol. 26:1997;1104-1110.
59. Moreau R, Lee SS, Hadengue A, Braillon A, Lebrec D. Hemodynamic effects of a clonidine-induced decrease in sympathetic tone in patients with cirrhosis. Hepatology. 7:1987;149-154.
60. Roulot D, Moreau R, Gaudin C, Bacq Y, Braillon A, Hadengue A, et al. Long-term sympathetic and hemodynamic responses to clonidine in patients with cirrhosis and ascites. Gastroenterology. 102:1992;1309-1318.
61. Albillos A, Banares R, Barrios C, Clemente C, Rossi I, Escartin P, et al. Oral administration of clonidine in patients with alcoholic cirrhosis. Hemodynamic and liver function effects. Gastroenterology. 102:1992;248-254.
62. Moreau R, Komeichi H, Kirstetter P, Ohsuga M, Cailmail S, Lebrec D. Altered control of vascular tone by adenosine triphosphate-sensitive potassium channels in rats with cirrhosis. Gastroenterology. 106:1994;1016-1023.
63. + channels by glibenclamide reduces portal pressure and hyperkinetic circulation in portal hypertensive rats. J Hepatol. 16:1992;215-218.
64. Piczueta MP, Piqué JM, Bosch J, Whittle BJR, Moncada S. Effects of inhibiting nitric oxide biosynthesis on the systemic and splanchnic circulation of rats with portal hypertension. Br J Pharmacol. 105:1992;184-190.
65. Lee FY, Albillos A, Colombato LA, Groszmann RJ. The role of nitric oxide in the vascular hyporesponsiveness to methoxamine in portal hypertensive rats. Hepatology. 16:1992;1043-1048.
66. Pilette C, Kirstetter P, Sogni P, Cailmail S, Moreau R, Lebrec D. The effects of a nitric oxide biosynthesis inhibitor on hyperdynamic circulation in two models of portal hypertensive rats. J Hepatol Gastroenterol. 11:1995;1-6.
67. Sogni P, Yang S, Pilette C, Moreau R, Gadano A, Avenard G, et al. Acute and chronic haemodynamic effects of naftazone in portal hypertensive rats. Eur J Pharmacol. 1998;. (in press).
68. Midgley S, Grant IS, Haynes WG, Webb DJ. Nitric oxide in liver failure. Lancet. 338:1991;1590.
69. Oberti F, Sogni P, Cailmail S, Moreau R, Pipy B, Lebrec D. Role of prostacyclin in hemodynamic alterations in conscious rats with extrahepatic or intrahepatic portal hypertension. Hepatology. 18:1993;621-627.
70. Wu Y, Cartland Burns R, Sitzmann JV. Effects of nitric oxide and cyclooxygenase inhibition on splanchnic hemodynamics in portal hypertension. Hepatology. 18:1993;1416-1421.
71. 2+ concentrations in arterial myocytes and reduces hyperdynamic circulation in portal hypertensive rats. Hepatology. 22:1995;168A.
72. Jones AL, Hayes PC. Organic nitrates in portal hypertension. Am J Gastroenterol. 89:1994;7-14.
73. Moreau R, Lebrec D. Nitrovasodilators and portal hypertension. J Hepatol. 10:1990;263-267.
74. Forest EH, Jalan R, Redhead DN, Hayes PC. Differing actions of the acute administration of propranolol and isosorbide-5-mononitrate on the portal circulation. Aliment Pharmacol Ther. 10:1996;795-800.
75. 2-adrenoceptor agonist, in conscious rats with secondary biliary cirrhosis. Hepatology. 15:1992;459-463.
76. B receptor antagonist of endothelin in portal hypertension. Hepatology. 24:1996;316A.
77. Reichen J, Sägesser S. Endothelin inhibits microvascular exchange and endothelin antagonists improve microvascular exchange more in cirrhotic than in normal rat liver. Hepatology. 20:1994;202A.
78. Mills PR, Rae AP, Farah DA, Russell Rl, Lorimer AR, Carter DC. Comparison of three adrenoreceptor blocking agents in patients with cirrhosis and portal hypertension. Gut. 25:1984;73-78.
79. Albillos A, Lledo JL, Rossi I, Pérez-Paramo M, Tabuenca MJ, Banares R, et al. Continuous prazosin administration in cirrhotic patients: effects on portal hemodynamics and on liver and renal function. Gastroenterology. 109:1995;1257-1265.
80. Svoboda P, Ochmann J, Kantorova I. Effect of enalapril treatment and sclerotherapy of esophageal varices on hepatic hemodynamics in portal hypertension. Hepatogastroenterology. 39:1992;549-552.
81. Chiang HT, Cheng JS, Lin M, Tseng WS, Chang JM, Lai KH. Haemodynamic effects of enalaprilat on portal hypertension in patients with HBsAg-positive cirrhosis. J Gastroenterol Hepatol. 10:1995;256-260.
82. Huang YT, Wang GF, Chen CF, Chen CC, Hong CY, Yang MCM. Fructus aurantii reduced portal pressure in portal hypertensive rats. Life Sci. 57:1995;2011-2020.
83. Dagenais M, Pomier-Layrargues G, Rocheleau B, Giroux L, Huet PM. Systemic and splanchnic haemodynamic effects of pentifylline in rats with portal hypertension. Clin Sci. 83:1992;41-45.
84. Soupison T, Yang S, Bernard C, Moreau R, Kirstetter P, D'Almeida M, et al. Acute haemodynamic responses and inhibition of tumour necrosis factor-α by pentoxifylline in rats with cirrhosis. Clin Sci. 91:1996;29-33.
85. Sanchez S, Albornoz L, Bandi JC, Gerona S, Mastai R. Pentoxifylline, a drug with rheological effects, decreases portal pressure in an experimental model of cirrhosis. Eur J Gastroenterol Hepatol. 9:1997;27-31.
86. Oberti F, Pilette C, Rifflet H, Ma∴iga MY, Moreau A, Gallois Y, et al. Effects of simvastatin, pentoxifylline and spironolactone on hepatic fibrosis and portal hypertension in rats with bile duct ligation. J Hepatol. 26:1997;1363-1371.
87. Grangé JD, Jaillon P, Noblinski B, Faucherre V, Ballet F, Vasmant D, et al. La pentoxifylline: un traitement potentiel des cirrhoses avec hypertension portale. Gastroenterol Clin Biol. 11:1987;161A.
88. Cereda JM, Roulot D, Braillon A, Moreau R, Koshy A, Lebrec D. Reduction of portal pressure by acute administration of furosemide in patients with alcoholic cirrhosis. J Hepatol. 9:1989;246-251.
89. Okumura H, Aramaki T, Katsuta Y, Satomura K, Akaike M, Sekiyama T, et al. Reduction in hepatic venous pressure gradient as a consequence of volume contraction due to chronic administration of spironolactone in patients with cirrhosis and no ascites. Am J Gastroenterol. 86:1991;46-52.
90. Garcia-Pagan JC, Salmeron JM, Feu F, Luca A, Ginés P, Pizcueta P, et al. Effects of low-sodium diet and spironolactone on portal pressure in patients with compensated cirrhosis. Hepatology. 19:1994;1095-1099.
91. Koda M, Murawaki Y, Kawasaki H, Ikawa S. Effects of canrenoate potassium, an aldosterone antagonist, on portal hemodynamics in patients with compensated liver cirrhosis. Hepatogastroenterology. 43:1996;887-892.
92. Nevens F, Lijnen P, Van Villoen H, Fevery J. The effect of long-term treatment with spironolactone on variceal pressure in patients with portal hypertension without ascites. Hepatology. 23:1996;1047-1052.
93. Van De Casteele M, Van Roey G, Nevens F, Fevery J. Effects of varying doses of spironolactone without and with nitrates on portal vein pressure and kidney function in partial portal vein ligated rats. Hepatology. 24:1996;1492-1516.
94. Lebrec D. Portal hypertension: serotonin and pathogenesis. Cardiovasc Drugs Ther. 4:1990;31-33.
95. Beaudry P, Hadengue A, Callebert J, Gaudin C, Soliman H, Moreau R, et al. Blood and plasma 5-hydroxytryptamine levels in patients with cirrhosis. Hepatology. 20:1994;800-803.
96. Hadengue A, Lee SS, Moreau R, Braillon A, Lebrec D. Beneficial hemodynamic effects of ketanserin in patients with cirrhosis: possible role of serotonergic mechanisms in portal hypertension. Hepatology. 7:1987;644-647.
97. Vorobioff J, Garcia-Tsao G, Groszmann R, Aceves G, Picabea E, Villavicencio R, et al. Long-term hemodynamic effects of ketanserin, a 5-hydroxytryptamine blocker, in portal hypertensive patients. Hepatologgy. 8:1989;88-91.
98. Mastai R, Giroux L, Semret M, Huet PM. Ritanserin decreases portal pressure in conscious and unrestrained cirrhotic rats. Gastroenterology. 98:1990;141-145.
99. 2-serotonergic antagonist, on portal pressure and splanchnic hemodynamics in portal hypertensive rats. Hepatology. 14:1991;1174-1178.
100. Yang NC, Pang PKT, Lay CS, Wu SL, Jan KM, Tsai YT, et al. Effect of parathyroid hormone on portal pressure in portal hypertensive rats. Liver. 10:1990;11-16.
101. Chao TW, Yu PC, Kuo JS, Pang PKT, Yang MCM. Responsiveness to synthetic parathyroid hormone in the portal vein of portal hypertensive rats. J Hepatol. 16:1992;326-331.
102. Sekiyama T, Gaudin C, Roulot D, Lebrec D, Braquet P, Braillon A. Evidence for platelet-activating factor as a mediator for hyperdynamic circulation in conscious cirrhotic rats. Braquet P. Ginkgolides - Chemistry, Biology, Pharmacology and Clinical Perspectives. 1989;313-319 Prous Sciences Publisher, Barcelona.
103. Lee FY, Tsai YT, Lin HC, Lee SD, Hsia HC, Lin WJ, et al. Hemodynamic effects of a combination of vasopressin and ketanserin in patients with hepatitis B-related cirrhosis. J Hepatol. 15:1992;54-58.
104. Lebrec D, Moreau R, Cailmail S, Sogni P, Oberti F, Hadengue A. Effects of terlipressin on hemodynamics and oxygen content in conscious portal vein stenosed and cirrhotic rats receiving propranolol. J Hepatol. 17:1993;102-107.
105. Moreau R, Cailmail S, Gadano A, Valla D, Lebrec D. Haemodynamic effects of octreotide in portal hypertensive rats receiving propranolol. Aliment Pharmacol Ther. 11:1997;775-779.
106. Vachiery F, Moreau R, Gadano A, Yang S, Sogni P, Hadengue A, et al. Hemodynamic and metabolic effects of terlipressin in patients with cirrhosis receiving a nonselective β-blocker. Dig Dis Sci. 41:1996;1722-1726.